Ubs Group Ag Exelixis, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Exelixis, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 576,709 shares of EXEL stock, worth $19.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

576,709

Previous 634,892 9.16%

Holding current value

$19.9 Million

Previous $14.3 Million 4.9%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $1.28 Million - $1.61 Million	-58,183 Reduced 9.16%	576,709 $15 Million
Q2 2024 Aug 13, 2024	BUY	$20.34 - $23.73 $2.65 Million - $3.09 Million	130,066 Added 25.76%	634,892 $14.3 Million
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $1.22 Million - $1.44 Million	60,289 Added 13.56%	504,826 $12 Million
Q4 2023 Feb 09, 2024	SELL	$19.25 - $24.13 $1.73 Million - $2.17 Million	-90,046 Reduced 16.84%	444,537 $10.7 Million
Q3 2023 Nov 09, 2023	BUY	$19.04 - $22.74 $3.11 Million - $3.71 Million	163,214 Added 43.95%	534,583 $11.7 Million
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $569,774 - $642,211	-31,358 Reduced 7.79%	371,369 $7.1 Million
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $3.65 Million - $4.34 Million	-223,730 Reduced 35.71%	402,727 $7.82 Million
Q4 2022 Feb 08, 2023	BUY	$14.96 - $17.39 $6.84 Million - $7.95 Million	457,171 Added 270.06%	626,457 $10 Million
Q3 2022 Nov 10, 2022	SELL	$15.68 - $22.27 $7.35 Million - $10.4 Million	-468,535 Reduced 73.46%	169,286 $2.65 Million
Q2 2022 Aug 10, 2022	BUY	$17.44 - $23.16 $6.9 Million - $9.16 Million	395,724 Added 163.46%	637,821 $13.3 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $6.53 Million - $8.69 Million	-383,276 Reduced 61.29%	242,097 $5.49 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $2.41 Million - $3.32 Million	151,865 Added 32.07%	625,373 $11.4 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $1.38 Million - $1.79 Million	84,727 Added 21.79%	473,508 $10 Million
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $1.09 Million - $1.55 Million	60,625 Added 18.47%	388,781 $7.08 Million
Q1 2021 May 12, 2021	BUY	$20.53 - $25.22 $3.25 Million - $4 Million	158,513 Added 93.44%	328,156 $7.41 Million
Q4 2020 Feb 11, 2021	BUY	$18.39 - $24.8 $240,614 - $324,483	13,084 Added 8.36%	169,643 $3.41 Million
Q3 2020 Nov 12, 2020	BUY	$20.67 - $26.94 $1.75 Million - $2.28 Million	84,517 Added 117.32%	156,559 $3.83 Million
Q2 2020 Jul 31, 2020	SELL	$16.46 - $27.42 $470,344 - $783,526	-28,575 Reduced 28.4%	72,042 $1.71 Million
Q1 2020 May 01, 2020	SELL	$14.46 - $21.8 $3.51 Million - $5.29 Million	-242,444 Reduced 70.67%	100,617 $1.73 Million
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $4.11 Million - $5.13 Million	-271,390 Reduced 44.17%	343,061 $6.04 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $6.4 Million - $8.2 Million	362,021 Added 143.41%	614,451 $10.9 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $333,262 - $435,723	17,605 Added 7.5%	252,430 $5.39 Million
Q1 2019 May 14, 2019	SELL	$19.6 - $24.76 $5.31 Million - $6.71 Million	-270,920 Reduced 53.57%	234,825 $5.59 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $3.74 Million - $5.98 Million	274,190 Added 118.41%	505,745 $9.95 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $2.14 Million - $3.02 Million	134,647 Added 138.94%	231,555 $4.1 Million
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $5.5 Million - $6.65 Million	-296,208 Reduced 75.35%	96,908 $2.09 Million
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $5.39 Million - $7.76 Million	243,361 Added 162.51%	393,116 $8.71 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $1.47 Million - $1.88 Million	-60,853 Reduced 28.89%	149,755 $4.55 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $2.91 Million - $3.65 Million	124,659 Added 145.04%	210,608 $5.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	53,390 Added 163.98%	85,949 $2.12 Million
Q1 2017 Nov 14, 2017	BUY	N/A	32,559	32,559 $706,000

Others Institutions Holding EXEL

# of Institutions

504

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account